Skip to content

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
15%+3.8pp
Amgen logo
AmgenAMGN
21%+3.6pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-188.2%-55.4pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-156.4%-47.5pp
Immunome logo
ImmunomeIMNM
-5,593.8%-11,284pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-2,554.1%-745pp

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: IDEAYA Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s net margin?
IDEAYA Biosciences, Inc. (IDYA) reported net margin of -3,921.1% in Q4 2024.
How has IDEAYA Biosciences, Inc.'s net margin changed year-over-year?
IDEAYA Biosciences, Inc.'s net margin decreased by 711.7% year-over-year, from -483.1% to -3,921.1%.
What is the long-term trend for IDEAYA Biosciences, Inc.'s net margin?
Over 3 years (2021 to 2024), IDEAYA Biosciences, Inc.'s net margin has grown at a 180.3% compound annual growth rate (CAGR), from -178.1% to -3,921.1%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.